Industry Growth Insights published a new data on “Mental Disorders Drugs Market”. The research report is titled “Mental Disorders Drugs Market research by Types (Drugs for Schizophrenia, Antidepressants, Antipsychotics, Anxiolytics, Drugs for the Treatment of Substance and Alcohol Addiction, Drugs for Childhood and Adolescent Mental Illness, Drugs to Treat Cognitive Disorders, Sleep Disorders, Others), By Applications (Children, Adolescents, Adults), By Players/Companies Johnson & Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Mental Disorders Drugs Market Research Report
By Type
Drugs for Schizophrenia, Antidepressants, Antipsychotics, Anxiolytics, Drugs for the Treatment of Substance and Alcohol Addiction, Drugs for Childhood and Adolescent Mental Illness, Drugs to Treat Cognitive Disorders, Sleep Disorders, Others
By Application
Children, Adolescents, Adults
By Companies
Johnson & Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Mental Disorders Drugs Market Report Segments:
The global Mental Disorders Drugs market is segmented on the basis of:
Types
Drugs for Schizophrenia, Antidepressants, Antipsychotics, Anxiolytics, Drugs for the Treatment of Substance and Alcohol Addiction, Drugs for Childhood and Adolescent Mental Illness, Drugs to Treat Cognitive Disorders, Sleep Disorders, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Adolescents, Adults
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Pfizer
- Eli Lilly
- GlaxoSmithKline
- AstraZeneca
- Bristol-Myers Squibb
- Abbott Laboratories
Highlights of The Mental Disorders Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drugs for Schizophrenia
- Antidepressants
- Antipsychotics
- Anxiolytics
- Drugs for the Treatment of Substance and Alcohol Addiction
- Drugs for Childhood and Adolescent Mental Illness
- Drugs to Treat Cognitive Disorders
- Sleep Disorders
- Others
- By Application:
- Children
- Adolescents
- Adults
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mental Disorders Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mental disorders drugs are medications used to treat mental disorders.
Some of the major companies in the mental disorders drugs market are Johnson & Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mental Disorders Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mental Disorders Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mental Disorders Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mental Disorders Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mental Disorders Drugs Market Size & Forecast, 2018-2028
4.5.1 Mental Disorders Drugs Market Size and Y-o-Y Growth
4.5.2 Mental Disorders Drugs Market Absolute $ Opportunity
Chapter 5 Global Mental Disorders Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Mental Disorders Drugs Market Size Forecast by Type
5.2.1 Drugs for Schizophrenia
5.2.2 Antidepressants
5.2.3 Antipsychotics
5.2.4 Anxiolytics
5.2.5 Drugs for the Treatment of Substance and Alcohol Addiction
5.2.6 Drugs for Childhood and Adolescent Mental Illness
5.2.7 Drugs to Treat Cognitive Disorders
5.2.8 Sleep Disorders
5.2.9 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Mental Disorders Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Mental Disorders Drugs Market Size Forecast by Applications
6.2.1 Children
6.2.2 Adolescents
6.2.3 Adults
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mental Disorders Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mental Disorders Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Mental Disorders Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Mental Disorders Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Mental Disorders Drugs Market Size Forecast by Type
9.6.1 Drugs for Schizophrenia
9.6.2 Antidepressants
9.6.3 Antipsychotics
9.6.4 Anxiolytics
9.6.5 Drugs for the Treatment of Substance and Alcohol Addiction
9.6.6 Drugs for Childhood and Adolescent Mental Illness
9.6.7 Drugs to Treat Cognitive Disorders
9.6.8 Sleep Disorders
9.6.9 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Mental Disorders Drugs Market Size Forecast by Applications
9.10.1 Children
9.10.2 Adolescents
9.10.3 Adults
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Mental Disorders Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Mental Disorders Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Mental Disorders Drugs Market Size Forecast by Type
10.6.1 Drugs for Schizophrenia
10.6.2 Antidepressants
10.6.3 Antipsychotics
10.6.4 Anxiolytics
10.6.5 Drugs for the Treatment of Substance and Alcohol Addiction
10.6.6 Drugs for Childhood and Adolescent Mental Illness
10.6.7 Drugs to Treat Cognitive Disorders
10.6.8 Sleep Disorders
10.6.9 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Mental Disorders Drugs Market Size Forecast by Applications
10.10.1 Children
10.10.2 Adolescents
10.10.3 Adults
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Mental Disorders Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Mental Disorders Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Mental Disorders Drugs Market Size Forecast by Type
11.6.1 Drugs for Schizophrenia
11.6.2 Antidepressants
11.6.3 Antipsychotics
11.6.4 Anxiolytics
11.6.5 Drugs for the Treatment of Substance and Alcohol Addiction
11.6.6 Drugs for Childhood and Adolescent Mental Illness
11.6.7 Drugs to Treat Cognitive Disorders
11.6.8 Sleep Disorders
11.6.9 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Mental Disorders Drugs Market Size Forecast by Applications
11.10.1 Children
11.10.2 Adolescents
11.10.3 Adults
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Mental Disorders Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Mental Disorders Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Mental Disorders Drugs Market Size Forecast by Type
12.6.1 Drugs for Schizophrenia
12.6.2 Antidepressants
12.6.3 Antipsychotics
12.6.4 Anxiolytics
12.6.5 Drugs for the Treatment of Substance and Alcohol Addiction
12.6.6 Drugs for Childhood and Adolescent Mental Illness
12.6.7 Drugs to Treat Cognitive Disorders
12.6.8 Sleep Disorders
12.6.9 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Mental Disorders Drugs Market Size Forecast by Applications
12.10.1 Children
12.10.2 Adolescents
12.10.3 Adults
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Mental Disorders Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Mental Disorders Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Mental Disorders Drugs Market Size Forecast by Type
13.6.1 Drugs for Schizophrenia
13.6.2 Antidepressants
13.6.3 Antipsychotics
13.6.4 Anxiolytics
13.6.5 Drugs for the Treatment of Substance and Alcohol Addiction
13.6.6 Drugs for Childhood and Adolescent Mental Illness
13.6.7 Drugs to Treat Cognitive Disorders
13.6.8 Sleep Disorders
13.6.9 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Mental Disorders Drugs Market Size Forecast by Applications
13.10.1 Children
13.10.2 Adolescents
13.10.3 Adults
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mental Disorders Drugs Market: Competitive Dashboard
14.2 Global Mental Disorders Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Pfizer
14.3.3 Eli Lilly
14.3.4 GlaxoSmithKline
14.3.5 AstraZeneca
14.3.6 Bristol-Myers Squibb
14.3.7 Abbott Laboratories
